Individuals with digestive disorders, such as Crohns disease or celiac disease, or other conditions that interfere with nutrient absorption
Mechanism in research How BPC-157 + TB-500 Blend is studied In published research BPC-157 was associated with accelerated tissue healing across animal injury models, while Thymosin Beta-4 (the parent of TB-500) was reported to support cell migration, angiogenesis, and tissue repair
The clinical drug development program was halted in 2007 after the pivotal Phase IIb trial did not show statistically significant weight loss in the primary endpoint
Side Effects and Safety Considerations While BPC 157 appears to have a relatively favourable safety profile, it has only been studied on animals
It centres around a dominant 50mg GHK CU core, supported by three additional compounds that are included at practical, usable levels